These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 26961140

  • 1. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
    Bulfoni M, Gerratana L, Del Ben F, Marzinotto S, Sorrentino M, Turetta M, Scoles G, Toffoletto B, Isola M, Beltrami CA, Di Loreto C, Beltrami AP, Puglisi F, Cesselli D.
    Breast Cancer Res; 2016 Mar 09; 18(1):30. PubMed ID: 26961140
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K, Kong YY, Dai B, Ye DW, Qu YY, Wang Y, Jia ZW, Li GX.
    Oncotarget; 2015 Dec 08; 6(39):41825-36. PubMed ID: 26497689
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
    Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T.
    Breast Cancer Res; 2012 Jan 20; 14(1):R15. PubMed ID: 22264265
    [Abstract] [Full Text] [Related]

  • 8. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
    Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D, Wagner J, Kimmig R, Kasimir-Bauer S.
    Oncotarget; 2016 Jul 05; 7(27):41677-41690. PubMed ID: 27223437
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA, Aggouraki D, Vetsika EK, Xenidis N, Kallergi G, Kotsakis A, Georgoulias V.
    Anticancer Res; 2021 Feb 05; 41(2):661-670. PubMed ID: 33517270
    [Abstract] [Full Text] [Related]

  • 11. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer.
    Giordano A, Gao H, Anfossi S, Cohen E, Mego M, Lee BN, Tin S, De Laurentiis M, Parker CA, Alvarez RH, Valero V, Ueno NT, De Placido S, Mani SA, Esteva FJ, Cristofanilli M, Reuben JM.
    Mol Cancer Ther; 2012 Nov 05; 11(11):2526-34. PubMed ID: 22973057
    [Abstract] [Full Text] [Related]

  • 12. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, von Ahsen O.
    BMC Cancer; 2012 May 16; 12():178. PubMed ID: 22591372
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X, Ma F, Liu S, Wu S, Xiao R, Yuan L, Sun X, Yi Z, Yang H, Xu B.
    Oncotarget; 2016 Oct 04; 7(40):65993-66002. PubMed ID: 27602758
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients.
    Wallwiener M, Riethdorf S, Hartkopf AD, Modugno C, Nees J, Madhavan D, Sprick MR, Schott S, Domschke C, Baccelli I, Schönfisch B, Burwinkel B, Marmé F, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A.
    BMC Cancer; 2014 Jul 11; 14():512. PubMed ID: 25015676
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers combined with clinicopathological risk has potential to better predict recurrence in stage III breast cancer treated with neoadjuvant chemotherapy: a pilot study.
    Du KY, Wu S, Ma X, Liu Y.
    Breast Cancer Res Treat; 2024 Oct 11; 207(3):517-527. PubMed ID: 38990453
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.